Stratec Se (SBS.DE) Stock Price
Stratec Se Price
Revenue has compounded at 7.6% per year over the past 18 years to 250.86 M EUR. Earnings per share have grown at 5.8% per year over the last 16 years. Stratec Se's net margin stands at -0.1%, down from 13.9% several years earlier. Stratec Se currently offers a dividend yield of about 2.39%. The dividend has grown at 9.9% per year over the past 19 years. Analysts set a median price target of 31.11 EUR, implying 23.7% above the current price. Of 11 analysts, 8 rate the stock a buy — an overall Buy consensus.
Stratec Se stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Stratec Se business model & stock analysis
Frequently asked questions about Stratec Se
The business model of Stratec SE revolves around providing innovative solutions and services to the diagnostics industry. As a leading global technology partner, Stratec SE specializes in developing and producing automated analyzer systems that enable fast, reliable, and cost-effective diagnostics. By focusing on instrument and assay integration, Stratec SE helps its customers streamline their processes and improve laboratory efficiency. The company's comprehensive portfolio covers a wide range of applications, including clinical diagnostics, blood banking, and pharmaceutical quality control. With its expertise and cutting-edge technologies, Stratec SE aims to drive advancements in diagnostics and contribute to improving patient care worldwide.
Stratec SE is primarily active in the life sciences and medical technology industries.
The main competitors of Stratec SE in the market include companies like Thermo Fisher Scientific, Becton, Dickinson and Company, PerkinElmer Inc., and Bio-Rad Laboratories.
Stratec SE, a leading global supplier of laboratory automation and diagnostic solutions, has a rich history and background. Established in 1979 in Birkenfeld, Germany, the company has grown from a small start-up to a renowned player in the life science industry. Stratec SE specializes in developing innovative technologies and devices that enable faster and more efficient diagnostics and research processes. With a strong focus on customer satisfaction and strategic partnerships, Stratec SE has expanded its presence worldwide. Today, the company serves a diverse range of customers, including pharmaceutical firms, medical device manufacturers, and research institutions. Stratec SE's dedication to technological advancement and commitment to quality make it a trusted name in the industry.
Stratec SE, a renowned stock company, has accomplished several notable milestones throughout its journey. One prominent achievement is the successful development of innovative laboratory and diagnostic solutions for the global healthcare industry. Stratec SE has also gained recognition for its strategic partnerships and collaborations, fostering growth and expanding its market presence. Moreover, the company has consistently delivered strong financial performance, achieving sustainable revenue growth and enhancing shareholder value. Stratec SE's commitment to continuous innovation, dedication to quality, and focus on customer satisfaction has positioned it as a key player in the industry, ensuring its ongoing success and reputation as a trusted stock investment.
Stratec SE is primarily present in various countries and regions. As a global company, its presence extends across Europe, North America, and Asia. Stratec SE operates in countries such as Germany, Switzerland, the United States, China, and Japan, among others. With its strong international footprint, Stratec SE has established itself as a leading provider of innovative solutions in the fields of in-vitro diagnostics and life sciences.
Stratec SE represents a strong set of values and corporate philosophy. With a focus on innovation and quality, the company aims to provide cutting-edge solutions in the field of automation and instrumentation for medical diagnostics. Stratec SE puts a strong emphasis on customer satisfaction and long-term partnerships, striving for continuous improvement and excellence. By fostering a culture of collaboration, integrity, and professionalism, the company aims to drive sustainable growth and deliver value to its shareholders. Stratec SE's commitment to delivering high-performance products and services, coupled with its dedication to corporate responsibility, sets it apart in the industry.
Analysts currently set an average price target of 34.95 EUR for the Stratec Se stock (median: 31.11 EUR), implying +39.0 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Stratec Se stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Stratec Se to generate revenue of 266.30 M EUR and earnings per share of 1.41 EUR.
The Stratec Se share (SBS.DE) is listed on 8 stock exchanges, including: London (0RAR.L), SIX (Zürich) (SBS.SW), XETRA (SBS.DE), Frankfurt (SBS.F), München (SBS.MU), Düsseldorf (SBS.DU), Hamburg (SBS.HM).
Stratec SE is a leading provider of automation solutions for the diagnostic and analytic industry. The company offers a wide portfolio of products and services that are part of its core business. Stratec operates in two business segments: instrumentation and diagnostics. (Instrumentation) Stratec offers a wide range of automation solutions, including the development, production, and distribution of equipment and systems for automated sample processing in clinical laboratories, as well as industrial automation for the production of medical devices and system solutions in the fields of life science and diagnostics. The company is a market leader in immunology and hematology and is also present in other segments such as microbiology and molecular biology. (Diagnostics) The diagnostic business segment provides specialized immunological and molecular tests for a variety of medical applications in the in vitro diagnostic (IVD) market. The company focuses on immuno-oncology, gastroenterology, infectious diseases, and cardiovascular diseases. Stratec offers comprehensive development, production, quality control, life cycle, and market release management services. The company emphasizes close collaboration with its customers to develop innovative solutions of the highest quality that meet the highest requirements for precision, reliability, and scalability. Stratec has demonstrated its resilience, successfully navigating through the COVID-19 pandemic in 2020. The company has proven to be crisis-resistant and has guided its employees through the crisis. With a strong global presence and industry-specific expertise, Stratec is able to continuously meet customer requirements. The company has established its business in the United Kingdom and the United States and plans to expand into other countries, primarily in Asia. Wherever Stratec operates, it emphasizes open and collaborative partnerships with customers and other stakeholders. Overall, Stratec SE is a company that impresses with its comprehensive automation solutions for the diagnostic and analytic industry. The instrumentation business segment covers multiple areas of medicine, while the diagnostics business segment specializes in the development and production of diagnostic solutions. Together, both segments enable optimal collaboration with customers and comprehensive expertise in the industry. The company is capable of addressing both customer needs and industry requirements as a whole.
The expected revenue of Stratec Se is 266.30 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Stratec Se is 17.17 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Stratec Se is currently 17.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stratec Se stock.
The price-to-sales ratio (P/S) of Stratec Se is currently 1.15. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stratec Se stock.
The Eulerpool Quality Score for Stratec Se is 2/10.
The ISIN of Stratec Se is DE000STRA555. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Stratec Se is STRA55. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Stratec Se is SBS.DE. The ticker symbol is used to trade Stratec Se shares on the stock exchange.
Stratec Se stock
Stratec Se Peer Group
Stratec Se Ticker
Stratec Se FIGI
All fundamentals and in-depth analysis of Stratec Se
Our stock analysis for Stratec Se stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stratec Se. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.